The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Clinical Outcome in a Randomized 1-Year Trial of Clozapine Versus Treatment as Usual for Patients With Treatment-Resistant Illness and a History of Mania
Abstract
Objective: Case series and follow-up studies suggest that clozapine may have mood-stabilizing properties in addition to antipsychotic action in patients with schizoaffective disorder, bipolar type, and bipolar I disorder, but the generalizability of these findings is limited. This article describes a randomized, open study of clozapine add-on therapy versus treatment as usual for patients with treatment-resistant illness and a history of mania. Method: Thirty-eight patients meeting the DSM-IV criteria for schizoaffective or bipolar disorder that was deemed treatment-resistant were randomly assigned to clozapine add-on treatment (N=19) or treatment as usual (no clozapine) (N=19) and followed up for 1 year. Patients received monthly ratings on the Brief Psychiatric Rating Scale, Clinical Global Impression scale, Bech-Rafaelsen Mania Scale, Hamilton Depression Rating Scale, Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms, Abnormal Involuntary Movement Scale, and a 40-item side effect checklist. Differences between treatment groups were assessed according to a pattern-mix random-regression model. An additional analysis compared group differences in rating scale scores against relative time in the study. Results: Significant between-group differences were found in scores on all rating scales except the Hamilton depression scale. Total medication use over 1 year significantly decreased in the clozapine group. No significant differences between groups in somatic complaints were noted. The subjects with nonpsychotic bipolar I disorder who received clozapine showed a degree of improvement similar to that of the entire clozapine-treated group. Clozapine dose was significantly higher for the patients with schizoaffective illness than for those with bipolar disorder. Conclusions: The results of this study support clozapine’s independent mood-stabilizing property. They demonstrate that clozapine use was associated with significant clinical improvement relative to treatment as usual.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Modeling the Drop-Out Mechanism in Repeated-Measures Studies
Little, R. J. A. (1995) · Journal of the American Statistical Association · doi:10.1080/01621459.1995.10476615 · Cited by 1,522
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
“Clozapine (Level 4)(163), and gabapentin (Level 4)(391) may also be useful adjunctive treatments for those who incompletely respond to first or second line therapies.”
BackgroundSelf-citationMeltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision)
Hirschfeld, R. M. A., Bowden, C. L., Gitlin, M. J., Keck, P. E., Perlis, R. H., Suppes, T., Thase, M. E., & Wagner, K. D. (2003) · Focus · doi:10.1176/foc.1.1.64 · Cited by 585
Self-citationSachs, G. S., Grossman, F., Ghaemi, S. N., Okamoto, A., & Bowden, C. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1146 · Cited by 424
Metadata
- Authors
- Suppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., & Rush, A. J.
- Venue
- Focus
- Published
- 2003-01
- Volume
- 1
- Issue
- 1
- Pages
- 37-43
- ISSN
- 1541-4094 (ISSN-L)
- 1541-4108
- OpenAlex
- W2161058570
- Cited by
- 197
- References
- 2
- FWCI
- 14.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.